{"url":"https://lda.senate.gov/api/v1/filings/c7072767-f123-4661-8fcf-4e9e044a95df/?format=json","filing_uuid":"c7072767-f123-4661-8fcf-4e9e044a95df","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2017,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c7072767-f123-4661-8fcf-4e9e044a95df/print/","filing_document_content_type":"text/html","income":null,"expenses":"180000.00","expenses_method":"c","expenses_method_display":"Method C - Reporting amounts under section 162(e) of the Internal Revenue Code","posted_by_name":"Paul Varki","dt_posted":"2017-07-27T12:42:50.247000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"600 LEE ROAD SUITE 100","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WAYNE","registrant_state":"PA","registrant_zip":"19087","registrant":{"id":401104361,"url":"https://lda.senate.gov/api/v1/registrants/401104361/?format=json","house_registrant_id":43561,"name":"ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)","description":"Specialty Pharmaceutical Company","address_1":"600 LEE ROAD SUITE 100","address_2":null,"address_3":null,"address_4":null,"city":"WAYNE","state":"PA","state_display":"Pennsylvania","zip":"19087","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MADELINE SCHERWITZKY","contact_telephone":"+1 425-523-8565","dt_updated":"2022-04-06T16:06:32.276341-04:00"},"client":{"id":201602,"url":"https://lda.senate.gov/api/v1/clients/201602/?format=json","client_id":12,"name":"ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)","general_description":"Registrant's name change from Egalet Corporation to Zyla Life Sciences","client_government_entity":false,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-02-20"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Issues related to DEA quotas of Schedule I and II controlled substances\nS. 524 (114th Congress): Provisions related to opioid treatment and abuse","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Abuse-deterrent opioid exclusivity policy issues\nH.R. 2025, provisions related to abuse-deterrent opioid exclusivity","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids\nH.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act\n1st Amendment/Communications with payors/off-label policy issues\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 1049, provisions related to physician education on abuse-deterrent opioid products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66526,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":"D","last_name":"MOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}